Table 1 Characteristics of CLL patients.

From: Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells

Patient

Sex

Age

Diagnose

Leukocytes/ml

Lymphocytes/ml

CD5

CD10

CD19

CD23

FMC

CD38

Surface chain

Cytogenetic/FISH

Prior treatment

1

F

82

CLL-B

70.100

63.300

+

+

+

Kappa

13q

Untreated

2

M

66

CLL-B

57.940

52.800

+

+

+

 

Lambda

 

Untreated

3

F

69

CLL-B

40.390

34.700

+

+

  

Negative

13q

Untreated

4

M

73

CLL-B

9.930

3.400

+

+

  

Kappa

 

Untreated

5

M

61

CLL-B

18.740

15.500

+

+

+

 

Kappa

No mutation

Untreated

6

M

84

CLL-B

28.050

22.000

+

+

+

+

Kappa

 

Untreated

  1. All of them present CD19 receptor and they were not treated before the collection of the sample. FMC refers to FMC-7 antigen, which is an epitope of CD20.